Libo Pharma Corp. (TPEX:7888)

Libo Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	42.41	27.69	10.99
Research & Development	265.92	123.46	41.08
Operating Expenses	308.32	151.16	48.91
Operating Income	-308.32	-151.16	-48.91
Interest Expense	-0.04	-0.05	-0.07
Interest & Investment Income	6.85	2.51	2.06
Currency Exchange Gain (Loss)	-	0.9	0.51
Other Non Operating Income (Expenses)	5.22	-	-
Pretax Income	-296.3	-147.8	-46.41
Net Income	-296.3	-147.8	-46.41
Net Income to Common	-296.3	-147.8	-46.41
Shares Outstanding (Basic)	63	37	27
Shares Outstanding (Diluted)	63	37	27
Shares Change (YoY)	66.87%	41.35%	-
EPS (Basic)	-4.74	-3.95	-1.75
EPS (Diluted)	-4.74	-3.95	-1.75
Free Cash Flow	-349.66	-119.84	-36.01
Free Cash Flow Per Share	-5.59	-3.20	-1.36
EBITDA	-284.78	-134.73	-45.1
D&A For EBITDA	23.55	16.43	3.81
EBIT	-308.32	-151.16	-48.91

Source: S&P Global Market Intelligence. Standard template. Financial Sources.